[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asd---atrial-septal-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asd---atrial-septal-defect":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100561461","abbott-structural-heart-device-registry-100561461",false,"NCT06590467","Abbott Structural Heart Device Registry","SH-Registry","Inclusion Criteria:\n\n1. Subject is expected to undergo an implant attempt using one or more Abbott Structural Heart devices covered in this Registry or has previously undergone an implant attempt within the timeframes specified in the device-specific appendices.\n2. Subject is willing and able to comply with the site's standard of care follow-up schedule.\n3. Subject is willing to provide appropriate informed consent for Registry participation. For deceased subjects enrolled retrospectively, local regulations and EC\u002FIRB recommendations regarding consent and the protection of personal data must be followed.\n\nExclusion Criteria:\n\n1\\. Subject is participating in another clinical study that would affect the results of this Registry.","ALL",{"count":18,"type":19},2500,"ESTIMATED","OBSERVATIONAL","The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017\u002F745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.",[23,24,25,26,27,28],"Heart Diseases","ASD - Atrial Septal Defect","VSD - Muscular Ventricular Septal Defect","PFO - Patent Foramen Ovale","PIVSD - Post Infarct Muscular Ventricular Septal Defect","Valvular Heart Disease",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"Amplatzer","Amplatzer Septal Occluder","Amplatzer Multi-fenestrated (Cribriform) Occluder","Amplatzer Duct Occluder","Amplatzer Piccolo Occluder","Amplatzer Muscular VSD Occluder","Amplatzer Post-Infarct VSD Occluder","Amplatzer Talisman","Amplatzer TorqVue Delivery System","Amplatzer Sizing Balloon","Amplatzer Guidewire","Amplatzer Occluder devices","Surgical Valves","Epic Plus Aortic Valve","Epic Plus Mitral Valve","Epic Plus Supra Aortic Valve","Epic Max Aortic Valve","Bioprosthetic heart valve","Surgical tissue heart valve","RECRUITING","2026-04-07",{"date":52,"type":53},"2026-04-13","ACTUAL",{"date":55,"type":53},"2024-08-21",{"date":57,"type":19},"2039-11",{"name":59,"class":60},"Abbott Medical Devices","INDUSTRY",28,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100613948","phase-4-a-multicenter-randomized-controlled-trial-of-echocardiography-guided-atrial-septal-defect-closure-performed-in-a-mobile-surgical-unit-100613948","NCT07273227","A Multicenter Randomized Controlled Trial of Echocardiography-Guided Atrial Septal Defect Closure Performed in a Mobile Surgical Unit","Inclusion Criteria:\n\n* Patients ≥8 years and able to undergo percutaneous intervention under local anesthesia.\n* Diagnosed with secundum ASD with a defect diameter of ≥6 mm and ≤36 mm, accompanied by right-sided volume overload.\n* Anatomical features suitable for transcatheter closure: the distance from the defect rim to the coronary sinus, superior vena cava, inferior vena cava, and pulmonary veins is ≥5 mm; and the distance to the mitral valves is ≥7 mm.\n\nExclusion Criteria:\n\n* Presence of primum ASD or sinus venosus ASD.\n* Infective endocarditis or intracardiac thrombus.\n* ASD with right-to-left shunting.\n* Concomitant intracardiac anomalies requiring simultaneous surgical repair.","8 Years",{"count":70,"type":19},300,"INTERVENTIONAL",[73],"PHASE4","Cardiovascular disease remains a major threat to global health, and structural heart disease which encompassing congenital heart defects, valvular disease, and cardiomyopathies constitutes a substantial proportion of its burden. Atrial septal defect (ASD) is among the most common congenital heart conditions, occurring in approximately 1.6 per 1,000 live births. Percutaneous closure of ASD has become the standard treatment due to its minimally invasive nature and proven efficacy. However, conventional closure procedures rely heavily on fluoroscopic guidance and iodinated contrast, which carry risks of radiation exposure, contrast-related harm, and limit applicability in specific patient groups. Moreover, such procedures must be performed in catheterization laboratories equipped with digital subtraction angiography systems.\n\nTo overcome these limitations, our team has spent over a decade developing a fully ultrasound-guided, radiation-free, contrast-free percutaneous intervention system-an original Chinese innovation that has pioneered \"no incision, no fluoroscopy, and no general anesthesia\" treatment for structural heart disease. This methodology has evolved into a comprehensive technical system and has been successfully applied to ASD, PFO, ventricular septal defect (VSD), patent ductus arteriosus (PDA), and several valvular disorders. It has been recognized by national clinical guidelines (2017), awarded the Chinese Medical Association First-Class Science and Technology Award (2022), and honored by the World Health Organization Innovation Award.\n\nBuilding upon the unique advantages of ultrasound-only guidance, we further developed a Mobile Surgical Vehicle. This mobile surgical unit integrates ultrasound imaging, sterilization, monitoring, and anesthesia equipment, enabling true \"hospital-free\" procedures for underserved regions lacking large medical devices. Early applications in remote areas of Southwest China and Belt-and-Road countries have demonstrated promising safety and feasibility.\n\nNevertheless, high-quality clinical evidence evaluating this mobile platform for ASD closure is lacking. To address this gap, we propose a multicenter randomized controlled trial to demonstrate that mobile-platform ultrasound-guided closure is non-inferior to conventional in-hospital ultrasound-guided procedures. This study will also refine methodology, workflow, and safety protocols for mobile interventional therapy. Its findings will provide essential evidence supporting this original Chinese technology, expand its international impact, and enable broader access for patients in remote regions.",[24],[77,78,79,80,81],"echocardiography-guided","percutaneous intervention","atrial septal defect","mobile surgical vehicle","mobile surgical unit","NOT_YET_RECRUITING","2025-12-07",{"date":85,"type":53},"2025-12-09",{"date":87,"type":19},"2025-12-19",{"date":89,"type":19},"2028-07-31",{"name":91,"class":92},"China National Center for Cardiovascular Diseases","OTHER_GOV",1]